Drug Trial Radar · NCT05369975
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Apr 19, 2022
Primary completion
Apr 21, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent kidney transplantation. Two non-comparative reference cohorts are included to assess the impact of differences in post-transplantation management and outcome in less sensitized patients.
Conditions
- Kidney Transplantation in Highly Sensitized Patients
Interventions
ImlifidaseDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Normal Transplantation RoutineOther
Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Graft failure-free survival 1 year after transplantation following imlifidase treatmentTime frame: 12 months after transplantation
Locations
22 sites in 11 countries. Site status is shown where the registry gives one.
Medizinische Universitaet Wien
Vienna, Austria
UZ Leuven - Campus Gasthuisberg
Leuven, Belgium
Institut klinicke a experimentalni mediciny (IKEM)
Prague, Czechia
Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, France
CHU de Grenoble - Hôpital Michallon
La Tronche, France
Hôpital Necker - Enfants Malades
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Klinikum rechts der Isar der Technische Universitaet Muenchen
Munich, Germany
Azienda Ospedaliera di Padova
Padova, Italy
Azienda Ospedaliero - Universitaria di Parma
Parma, Italy
University Medical Center Groningen
Groningen, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Department of Nephrology , Zaloška 7
Ljubljana, Slovenia
Hospital Del Mar, Servicio de Nefrología
Barcelona, Spain
Hospital Clínic de Barcelona, Unidad de Trasplante Renal
Barcelona, Spain
Vall d'Hebron University Hospital (HUVH)
Barcelona, Spain
Hospital 12 de Octubre
Madrid, Spain
Karolinska University Hospital
Huddinge, Sweden
Uppsala University Hospital
Uppsala, Sweden
St. James University Hospital
Leeds, United Kingdom
Leicester General Hospital
Leicester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.